论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Deng Y, Huang J, Zhang H, Zhu X, Gong Q
Received 10 September 2017
Accepted for publication 14 February 2018
Published 12 April 2018 Volume 2018:11 Pages 763—769
DOI https://doi.org/10.2147/JPR.S151350
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Katherine Hanlon
Background: Previous studies suggested that single-nucleotide polymorphisms in
dopamine receptor D2 (DRD2 ) are the
susceptibility loci for migraine. This study was aimed at evaluating the
contribution of DRD2 rs1800497
and its expression to migraine risk in Han Chinese subjects.
Methods: In total, 250 patients with migraine and 250 age- and sex-matched
control subjects were included in this study. TaqMan allelic discrimination
assay was used for DRD2 rs1800497
genotyping. Plasma DRD2 concentration
was determined using enzyme-linked immunosorbent assay.
Results: Significant associations were observed for the rs1800497 genotype
(χ 2=6.37, p =0.041) and allele
(χ 2=4.69, p =0.03; odds ratio
[OR]=1.33, 95% CI=1.03–1.72, power=58%) frequencies between the migraine and
control groups. Sex analysis indicated a positive association for rs1800497
between female patients with migraine and control individuals (genotype: χ 2=7.84, p =0.019;
allele: χ 2=6.60, p =0.010; OR=1.61,
95% CI=1.12–2.30, power=73.4%). Furthermore, a significant association was
observed only in female patients with migraine without aura (MO)
(genotype: χ 2=6.88, p =0.032;
allele: χ 2=5.65, p =0.017; OR=1.59,
95% CI=1.08–2.36, power=65.1%). The mean plasma DRD2 levels in the control
group (mean±SD: 24.20±2.78) were significantly lower than those in the migraine
with aura (MA) (30.86±3.69, p <0.0001) and MO
groups (31.88±4.99, p <0.0001).
Additionally, there was a sex-based difference in DRD2 expression in the MA
(male vs female: 29.46±3.59 vs 32.27±3.27, p <0.01)
and MO groups (male vs female: 29.18±3.50 vs 34.58±4.84, p <0.0001). Moreover, plasma
DRD2 levels in patients were significantly different among the three genotypes
(CC vs CT vs TT: 24.76±3.76 vs 30.93±3.85 vs 37.06±3.95, p <0.0001). Similar results were
observed both in the MA (CC vs CT vs TT: 25.09±3.84 vs 28.57±2.84 vs
33.37±1.58, p <0.0001) and MO groups (CC vs
CT vs TT: 24.65±3.79 vs 31.65±3.86 vs 38.29±3.74, p <0.0001).
Conclusion: Our case–control study suggested that the DRD2 polymorphism rs1800497
was significantly associated with the risk of migraine in Han Chinese females.
Additionally, the plasma DRD2 level was high in patients with migraine. Females
with migraine had considerably higher DRD2 levels than males with migraine.
DRD2 expression may be regulated by DRD2 rs1800497
genotype in patients with migraine.
Keywords: dopamine receptor D2, female, rs1800497, ELISA, migraine